HTD1801: Metabolic Dysfunction-associated Steatohepatitis (MASH)

NAFLD/MASH (Nonalcoholic Fatty Liver Disease / Metabolic Dysfunction-associated Steatohepatitis) is a range of liver conditions affecting people who drink little to no alcohol.


As reported by the National Institutes of Health, Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in the liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes fat to build up in the liver it is called alcoholic liver disease.

Two types of NAFLD are simple fatty liver and Metabolic Dysfunction-associated Steatohepatitis (MASH). Simple fatty liver and MASH are two separate conditions. People typically develop one type of NAFLD or the other, although sometimes people with one form are later diagnosed with the other form of NAFLD.

Simple fatty liver

Simple fatty liver, also called nonalcoholic fatty liver (NAFL), is a form of NAFLD in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not progress to cause liver damage or complications.


MASH is a form of NAFLD in which you have hepatitis—inflammation of the liver—and liver cell damage, in addition to fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. MASH may lead to cirrhosis or liver cancer.

Experts are not sure why some people with NAFLD have MASH while others have simple fatty liver.

How HTD1801 Should Help in MASH

As indicated by pharmacology studies and clinical studies, HTD1801 could improve liver histology features through the following factors:

● Decrease the NAFLD Score (NAS);

● Reduce liver inflammation, ballooning degeneration and steatosis;

● Decrease liver cholesterol and triglyceride;

● Decrease liver enzymes;

● Decrease serum LDL-c;

● Improve insulin sensitivity.

As MASH is a complex disease, combination therapy in HTD1801 can address multiple targets and pathways, as depicted by the figure on the right.

Market Overview

According to the consulting firm CIC: Metabolic Dysfunction-associated Steatohepatitis (MASH) has great market potential worldwide. From 2024 to 2032, the market size of MASH drugs will expand at a compound annual growth rate (CAGR) of 87.6% in China, the United States, and Europe.

According to MedCity News: During the next 10 years, the field is projected to swell forty-fold from $618 million in 2016 to $25.3 billion in 2026.

For more information on the MASH trial, please visit


We will contact you as soon as possible

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

© 2024 HighTide Therapeutics, Inc.

Legal StatementPrivacy PolicyCookie Policy


Follow Us

© 2024 HighTide Therapeutics, Inc.